Female fertility testing requires the careful evaluation of multiple organ systems, as well as a combination of diagnostic techniques. This includes the careful evaluation of reproductive anatomy and patient history by a trained fertility specialist, as well as accurate blood testing from a clinical laboratory exclusively focused on fertility testing.
A critical component of female fertility testing includes the accurate evaluation of ovarian reserve and ovulatory egg supply. ReproSource has invested heavily in conducting extensive egg supply research, and in developing calibrated and validated testing for the accurate evaluation of ovulatory egg supply.
The Ovarian Assessment Report (OAR)™ provides a highly accurate assessment of a woman’s ovulatory egg supply using a single blood sample. The OAR provides results from both routine diagnostics, such as FSH, and advanced hormone tests such as AMH. The OAR also includes age to provide an Egg Supply Score™ (ESS) which allows for a more accurate estimate of a woman’s available egg supply.
The OAR helps you accurately assess egg supply status for patients:
Visit ReproSource.com for detailed information about the OAR that is best for you and your patients.
ReproSource is a pioneer in establishing the clinical utility of AMH for fertility specialists and has calibrated the assay results to the number of eggs retrieved through ovarian hyperstimulation.
Although AMH has quickly been established as the most reliable single hormone measure of ovarian reserve, ReproSource continues to conduct research to develop more meaningful cutoff ranges for clinical conditions such as ovarian hyperstimulation syndrome (OHSS) and polycystic ovarian syndrome.
Why use ReproSource for AMH testing?
Visit ReproSource.com for more information on AMH research and ovarian reserve testing.
ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact.
Male fertility testing includes innovative semen and genetic testing coupled with robust and informative reporting that allows clinicians to quickly interpret test results and effectively communicate those results using patient-friendly language and graphics. Additionally, the andrology research and product development teams at ReproSource have developed male fertility testing solutions that feature:
The Advanced Semen Report 2.0 is a unique ReproSource panel that provides an evaluation of multiple semen parameters that have been shown to affect a couple’s likelihood of success with natural conception and intrauterine insemination (IUI).
Our proprietary Advanced Semen Report measures DNA fragmentation and ROS damage using only a single specimen, offering clinicians and patients more accurate expectations of IUI success. Clinical research indicates that abnormal DNA fragmentation index (DFI) scores predict a poor chance of success with IUI but improved intracytoplasmic sperm injection success relative to conventional IVF.
Visit ReproSource.com for more information on the Advanced Semen Report.
The semen analysis with @Home Collection is ideal for remote patients that are unable or prefer not to provide a semen specimen at a fertility treatment center or local laboratory. The semen analysis with @Home Collection utilizes a proprietary media and process that preserves semen parameters to ensure an accurate semen analysis the day after specimen collection, providing a highly accurate and convenient semen analysis alternative.
A comprehensive semen analysis:
The @Home Collection option is ideal for:
Easy and affordable:
Click here to learn more information about the robust validation studies or to order tests and panels.
ReproSource also offers unique male fertility testing that accurately identifies the genetic factors that impact male fertility. The ReproSource Y-Chromosome MicroDeletions (YCMD3.0™) test was developed in collaboration with world renowned scientists in the field of Y chromosome research.
In both azoospermic and oligospermic patients, the ReproSource Y-Chromosome MicroDeletions (YCMD3.0™) test:
ReproSource also provides chromosome karyotyping services. A karyotype is also recommended along with a Y microdeletion study for azoospermic or severely oligospermic males.
Visit ReproSource.com today to learn more about high quality, innovative diagnostic testing coupled with unparalleled service and commitment to excellence.
ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact.
QHerit®, our innovative genetic carrier screening portfolio provides clinically relevant, right-sized panels that deliver information that you and your patients need to help plan their futures.
ReproSource® empowers you to make the best decisions about patient fertility treatments, with access to a network of experts and high-quality testing.
Certified Genomic Science Specialists are available to help with test selection and results interpretation 1.866.GENE.INFO (1.866.436.3463)
Contact us to receive additional information on our lab tests, services, and coverage
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
